## 1 Introduction
In contrast, toctorienols and other related tocochromanol compounds are not well characterized and identified within natural ecosystems. Consequently, there are fewer studies documenting their identification, determination, biosynthesis, taxonomic distribution, biological functions in plants and humans, and metabolism, despite the potential health benefits associated with these molecules [14]. Current knowledge is mainly focused only on \(\alpha\)-T, the most well-studied tocochromanol for the prevention of human deficiency disease, specifically \"Ataxia with Vitamin E Deficiency\". Therefore, the term \"vitamin E\" must not be used for expressing or used synonymously for any other tocochromanol other than \(\alpha\)-T [15]. In 2016, it was estimated that fewer than 3% of investigations and clinical studies addressing the effects of tocochromanol supplementation on health focused on toctorienols, whereas over 97% were centered on tocopherols [16]. Despite numerous reports suggesting that toctorienols exhibit superior biological functions compared with tocopherols--such as enhanced anti-oxidant and anti-inflammatory properties and protective effects against cancer, cardiovascular diseases, diabetes, and neuro-degenerative disorders--these compounds remain less studied [16; 17; 18]. Tocotrienolsare safe, health-beneficial molecules (non-toxic to normal cells), possess anti-metastatic and anti-angiogenic properties, and specifically target and eliminate cancer stem cells. Therefore, their inclusion in mono-targeted and/or combinatorial therapy with other chemotherapeutic substances is encouraged [19]. For \(\alpha\)-T, there is the absence of evidence supporting its cancer-preventive activity. Regarding \(\delta\)-T, \(\gamma\)-T, and tocotrienols, their impact on cancer risk remains ambiguous and necessitates further investigation [20]. Well-designed clinical trials combining tocotrienols, nanotechnology (micelle complexes, liposomes, and nano emulsions), and quantitative structure-activity relationship models could lead to the emergence of nature-based therapeutic agents (tocotrienols as selective, cost-effective drugs) for the management of various malignancies or, at a minimum, their prevention [21]. Consequently, it is crucial to identify natural sources of tocotrienols that entail low costs for isolation and purification while also enhancing their delivery efficiency and bioavailability, in order to achieve the next milestone in cancer therapy via tocotrienols. Within the current market, several tea products under the name St. John's wort can be found. A recent investigation into the chemical profiling of St. John's wort products revealed significant variations in the quantified secondary metabolites in St. John's wort tea products [4]. To obtain extracts rich in hydrophilic phytochemicals from St. John's wort, at lab and industrial scales, pure water was typically applied [22; 23; 24]. Simultaneously, the home-made, lab, and industrial production of water extracts of hydrophilic bioactive compounds from St. John's wort does not consider the re-use of the generated plant residues (by-products) for the future re-extraction of other valuable phytochemicals with different properties, e.g., lipophilic tocochromanols. Therefore, obtaining tocotrienols from sustainable/natural sources is important. Hence, the objective of this study is to demonstrate that the medical potential of St. John's wort is higher than previously believed, attributable to the presence of rare premyllipids such as tocotrienols, and enhance the value of the processing chain to achieve the extraction of lipophilic bioactive phytochemicals after the extraction of hydrophilic compounds by water (tea infusions).